[ad_1]
Vector BioPharma AG (Vector BioPharma), a biopharmaceutical firm aiming to remodel the protection, efficacy, and specificity of drug supply to enhance therapies for sufferers, at this time introduced that it has entered right into a strategic, multi-phase collaboration with the Instituto de Biologia Experimental e Tecnológica (iBET), a world-leading research-intensive group specialised in biotechnology analysis and bioprocess improvement. The partnership goals to develop high-throughput quantification strategies to advance the technical improvement of Vector’s gene supply platform.
Vector BioPharma’s gene supply platform combines high-capacity virus-like particles with exogenous, high-avidity adapter proteins. Utilizing iBET’s experience in creating built-in bioprocesses and analytical strategies for the manufacturing, purification and characterization of virus-based prescription drugs, the collaboration shall be executed in a number of levels. Initially, the collaboration will search to develop a high-throughput analytical technique for full-to-empty capsid ratio quantification from each in-process and remaining purified samples. Monitoring the full-to-empty capsid ratio, which is a important high quality attribute of virus-based biotherapeutics, is used to find out the purity and security of such merchandise throughout the manufacturing course of and on the remaining product stage. Subsequent collaboration levels will give attention to the upstream course of improvement for the large-scale manufacturing of Vector BioPharma’s virus-like particles.
Lorenz Mayr, Ph.D., CEO at Vector BioPharma, stated: “Collaboration with industry-leading R&D institutions and researchers in the biopharmaceutical manufacturing sector is key to accelerating the development of Vector BioPharma’s proprietary gene delivery platform as we look towards large scale and GMP manufacturing. Considering iBET’s track record of prestigious RD&I technology transfer projects with companies across the globe, we are confident in this project to rapidly accelerate the development of our gene delivery platform.”
Micha Häuptle, Ph.D., Head of CMC at Vector BioPharma, stated: “We are delighted to enter a collaboration with iBET, a world-class expert in the field of manufacturing process and analytical development for viral vectors. We look forward to leveraging iBET’s experience in the virus-based biopharmaceutical sector, for the development of precise analytical methods and robust manufacturing processes for Vector BioPharma’s virus-like particles designed for precise gene delivery.”
Paula Alves, Ph.D., CEO at iBET, stated: “iBET is thrilled to partner with such a creative team as Vector BioPharma which, like us, excels at applying cutting-edge technologies from academic research to create innovative viral vectors for gene delivery. Vector BioPharma’s challenges to develop next-generation therapeutics for high-precision gene delivery will motivate our efforts to succeed. This partnership is iBET´s most recent contribution to global health initiatives with its bioprocess development and bioanalytics know-how to bring safe and improved medicines to the clinic.”
António Roldão, Ph.D., Coordinator of Late-stage R&D Bioproduction Unit at iBET, stated: “It is an honour that Vector Biopharma has appointed iBET to partner in the development of such an innovative and potentially transformative new modality. We are confident that the competences and expertise of iBET in bioprocess and analytics development for gene therapy applications will complement Vector BioPharma’s know-how on viral particles engineering to potentiate its innovative gene delivery platform. Looking forward to a fruitful and exciting collaboration.”